Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 593-599

  Schultze, Alexander ^a   Fiedler, Walter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angiogenesis; Chemoresistance; Focal adhesion kinase; Metastasis; Migration of tumor cells; Small molecule inhibitors

Indexed keywords

ANTHRACYCLINE; CAMPTOTHECIN; CHLOROPYRAMINE; CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; GEMCITABINE; GSK 2256098; MESSENGER RNA; NVP TAC 544; NVP TAE 226; PF 04554878; PF 562 271; PF 573 228; PLACEBO; PND 1186; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 3 INHIBITOR; Y 15;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ESOPHAGUS CANCER; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HEAD AND NECK CANCER; HUMAN; HYPERBILIRUBINEMIA; LUNG METASTASIS; MELANOMA CELL; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR; TUMOR GROWTH;

EID: 80051767224     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011796817727     Document Type: Review

References (88)

1. Kanner, S. B.; Reynolds, A. B.; Vines, R. R.; Parsons, J. T., Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc. Natl. Acad. Sci. U S A, 1990, 87 (9), 3328-3332.
2. Chatzizacharias, N. A.; Kouraklis, G. P.; Theocharis, S. E., Focal adhesion kinase: a promising target for anticancer therapy. Expert Opin. Ther. Targets, 2007, 11 (10), 1315-1328.
3. Han, E. K.; McGonigal, T., Role of focal adhesion kinase in human cancer: a potential target for drug discovery. Anticancer Agents Med. Chem., 2007, 7 (6), 681-684.
4. van Nimwegen, M. J.; van de Water, B., Focal adhesion kinase: a potential target in cancer therapy. Biochem. Pharmacol., 2007, 73 (5), 597-609.
5. Golubovskaya, V. M., Focal adhesion kinase as a cancer therapy target. Anticancer Agents Med. Chem., 2010, 10 (10), 735-741.
6. Schultze, A.; Fiedler, W., Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin. Investig. Drugs, 2010, 19 (6), 777-788.
7. Weiner, T. M.; Liu, E. T.; Craven, R. J.; Cance, W. G., Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors. Ann. Surg. Oncol., 1994, 1 (1), 18-27.
8. Cance, W. G.; Harris, J. E.; Iacocca, M. V.; Roche, E.; Yang, X.; Chang, J.; Simkins, S.; Xu, L., Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin. Cancer Res., 2000, 6 (6), 2417-2423.
9. Owens, L. V.; Xu, L.; Craven, R. J.; Dent, G. A.; Weiner, T. M.; Kornberg, L.; Liu, E. T.; Cance, W. G., Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res., 1995, 55 (13), 2752-2755.
10. Walsh, C.; Tanjoni, I.; Uryu, S.; Tomar, A.; Nam, J. O.; Luo, H.; Phillips, A.; Patel, N.; Kwok, C.; McMahon, G.; Stupack, D. G.; Schlaepfer, D. D., Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol. Ther., 9 (10).
11. Jan, Y. J.; Ko, B. S.; Hsu, C.; Chang, T. C.; Chen, S. C.; Wang, J.; Liou, J. Y., Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma. Hum. Pathol., 2009, 40 (10), 1384-1390.
12. Fujii, T.; Koshikawa, K.; Nomoto, S.; Okochi, O.; Kaneko, T.; Inoue, S.; Yatabe, Y.; Takeda, S.; Nakao, A., Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J. Hepatol., 2004, 41 (1), 104-111.
13. Yuan, Z.; Fan, J.; Wu, Z. Q.; Zhou, J.; Qiu, S. J., [Focal adhesion kinase mRNA overexpression in hepatocellular carcinoma HCC) and correlation thereof with prognosis of HCC]. Zhonghua Yi Xue Za Zhi, 2007, 87 (18), 1256-1259.
14. Lark, A. L.; Livasy, C. A.; Dressler, L.; Moore, D. T.; Millikan, R. C.; Geradts, J.; Iacocca, M.; Cowan, D.; Little, D.; Craven, R. J.; Cance, W., High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod. Pathol., 2005, 18 (10), 1289-1294.
15. Giaginis, C. T.; Vgenopoulou, S.; Tsourouflis, G. S.; Politi, E. N.; Kouraklis, G. P.; Theocharis, S. E., Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol. Oncol. Res., 2009, 15 (2), 173-181.
16. Gabriel, B.; Hasenburg, A.; Waizenegger, M.; Orlowska-Volk, M.; Stickeler, E.; zur Hausen, A., Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study. Int. J. Gynecol. Cancer, 2009, 19 (7), 1221-1225.
17. Tavernier-Tardy, E.; Cornillon, J.; Campos, L.; Flandrin, P.; Duval, A.; Nadal, N.; Guyotat, D., Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk. Res., 2009, 33 (6), 764-768.
18. Parsons, J. T.; Slack-Davis, J.; Tilghman, R.; Roberts, W. G., Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin. Cancer Res., 2008, 14 (3), 627-632.
19. Hayashi, A.; Aishima, S.; Inoue, T.; Nakata, K.; Morimatsu, K.; Nagai, E.; Oda, Y.; Tanaka, M.; Tsuneyoshi, M., Decreased expression of focal adhesion kinase is associated with a poor prognosis in extrahepatic bile duct carcinoma. Hum. Pathol., 2010, 41 (6), 859-866.
20. Ohta, R.; Yamashita, Y.; Taketomi, A.; Kitagawa, D.; Kuroda, Y.; Itoh, S.; Aishima, S.; Maehara, Y., Reduced expression of focal adhesion kinase in intrahepatic cholangiocarcinoma is associated with poor tumor differentiation. Oncology, 2006, 71 (5-6), 417-422.
21. Gabriel, B.; zur Hausen, A.; Stickeler, E.; Dietz, C.; Gitsch, G.; Fischer, D. C.; Bouda, J.; Tempfer, C.; Hasenburg, A., Weak expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with poor disease outcome. Clin. Cancer Res., 2006, 12 (8), 2476-2483.
22. Zheng, Y.; Lu, Z., Paradoxical roles of FAK in tumor cell migration and metastasis. Cell Cycle, 2009, 8 (21), 3474-3479.
23. Antonyak, M. A.; Cerione, R. A., Ras and the FAK paradox. Mol. Cell, 2009, 35 (2), 141-142.
24. Schaller, M. D., FAK and paxillin: regulators of N-cadherin adhesion and inhibitors of cell migration? J. Cell. Biol., 2004, 166 (2), 157-159.
25. Thiery, J. P.; Acloque, H.; Huang, R. Y.; Nieto, M. A., Epithelialmesenchymal transitions in development and disease. Cell, 2009, 139 (5), 871-890.
26. Avizienyte, E.; Frame, M. C., Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr. Opin. Cell. Biol., 2005, 17 (5), 542-547.
27. Cicchini, C.; Laudadio, I.; Citarella, F.; Corazzari, M.; Steindler, C.; Conigliaro, A.; Fantoni, A.; Amicone, L.; Tripodi, M., TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp. Cell Res., 2008, 314 (1), 143-152.
28. Maung, K.; Easty, D. J.; Hill, S. P.; Bennett, D. C., Requirement for focal adhesion kinase in tumor cell adhesion. Oncogene, 1999, 18 (48), 6824-6828.
29. Duxbury, M. S.; Ito, H.; Benoit, E.; Zinner, M. J.; Ashley, S. W.; Whang, E. E., RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem. Biophys. Res. Commun., 2003, 311 (3), 786-792.
30. Chen, Y. Y.; Wang, Z. X.; Chang, P. A.; Li, J. J.; Pan, F.; Yang, L.; Bian, Z. H.; Zou, L.; He, J. M.; Liang, H. J., Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance. Cancer Sci., 2009, 100 (9), 1708-1713.
31. Satoh, T. H.; Surmacz, T. A.; Nyormoi, O.; Whitacre, C. M., Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins. Biocell, 2003, 27 (1), 47-55.
32. Smith, C. S.; Golubovskaya, V. M.; Peck, E.; Xu, L. H.; Monia, B. P.; Yang, X.; Cance, W. G., Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5- fluorouracil on the viability of melanoma cell lines. Melanoma Res., 2005, 15 (5), 357-362.
33. Halder, J.; Kamat, A. A.; Landen, C. N., Jr.; Han, L. Y.; Lutgendorf, S. K.; Lin, Y. G.; Merritt, W. M.; Jennings, N. B.; Chavez-Reyes, A.; Coleman, R. L.; Gershenson, D. M.; Schmandt, R.; Cole, S. W.; Lopez-Berestein, G.; Sood, A. K., Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res., 2006, 12 (16), 4916-4924.
34. Wu, Z. M.; Yuan, X. H.; Jiang, P. C.; Li, Z. Q.; Wu, T., Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells. J. Neurooncol., 2006, 77 (2), 117-123.
35. van Nimwegen, M. J.; Huigsloot, M.; Camier, A.; Tijdens, I. B.; van de Water, B., Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells. Mol. Pharmacol., 2006, 70 (4), 1330-1339.
36. Zhang, H. M.; Keledjian, K. M.; Rao, J. N.; Zou, T.; Liu, L.; Marasa, B. S.; Wang, S. R.; Ru, L.; Strauch, E. D.; Wang, J. Y., Induced focal adhesion kinase expression suppresses apoptosis by activating NF-kappaB signaling in intestinal epithelial cells. Am. J. Physiol. Cell. Physiol., 2006, 290 (5), C1310-C1320.
37. Chen, Y.; Wang, Z.; Chang, P.; Xiang, L.; Pan, F.; Li, J.; Jiang, J.; Zou, L.; Yang, L.; Bian, Z.; Liang, H., The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas. Int. J. Cancer, 2009.
38. Golubovskaya, V. M.; Cance, W., Focal adhesion kinase and p53 signal transduction pathways in cancer. Front. Biosci., 2010, 15, 901-912.
39. Schaller, M. D., Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim. Biophys. Acta, 2001, 1540 (1), 1-21.
40. Zhao, J.; Guan, J. L., Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev., 2009, 28 (1-2), 35-49.
41. Brunton, V. G.; Frame, M. C., Src and focal adhesion kinase as therapeutic targets in cancer. Curr. Opin. Pharmacol., 2008, 8 (4), 427-432.
42. Mon, N. N.; Ito, S.; Senga, T.; Hamaguchi, M., FAK signaling in neoplastic disorders: a linkage between inflammation and cancer. Ann. N. Y. Acad. Sci., 2006, 1086, 199-212.
43. Golubovskaya, V.; Beviglia, L.; Xu, L. H.; Earp, H. S., 3rd; Craven, R.; Cance, W., Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J. Biol. Chem., 2002, 277 (41), 38978-38987.
44. Golubovskaya, V. M.; Gross, S.; Kaur, A. S.; Wilson, R. I.; Xu, L. H.; Yang, X. H.; Cance, W. G., Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines. Mol. Cancer Res., 2003, 1 (10), 755-764.
45. Beierle, E. A.; Ma, X.; Trujillo, A.; Kurenova, E. V.; Cance, W. G.; Golubovskaya, V. M., Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines. Mol. Carcinog., 2010, 49 (3), 224-234.
46. Garces, C. A.; Kurenova, E. V.; Golubovskaya, V. M.; Cance, W. G., Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res., 2006, 66 (3), 1446-1454.
47. Liu, W.; Bloom, D. A.; Cance, W. G.; Kurenova, E. V.; Golubovskaya, V. M.; Hochwald, S. N., FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis, 2008, 29 (6), 1096-1107.
48. Zheng, D.; Kurenova, E.; Ucar, D.; Golubovskaya, V.; Magis, A.; Ostrov, D.; Cance, W. G.; Hochwald, S. N., Targeting of the protein interaction site between FAK and IGF-1R. Biochem. Biophys. Res. Commun., 2009, 388 (2), 301-305.
49. Wang, S.; Basson, M. D., Akt directly regulates focal adhesion kinase through association and serine phosphorylation: implication for pressure-induced colon cancer metastasis. Am. J. Physiol. Cell. Physiol., 2011, 300 (3), C657-C670.
50. Carmeliet, P., Angiogenesis in health and disease. Nat. Med., 2003, 9 (6), 653-660.
51. Gehling, U. M.; Ergun, S.; Schumacher, U.; Wagener, C.; Pantel, K.; Otte, M.; Schuch, G.; Schafhausen, P.; Mende, T.; Kilic, N.; Kluge, K.; Schafer, B.; Hossfeld, D. K.; Fiedler, W., In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood, 2000, 95 (10), 3106-3112.
52. Ingram, D. A.; Mead, L. E.; Tanaka, H.; Meade, V.; Fenoglio, A.; Mortell, K.; Pollok, K.; Ferkowicz, M. J.; Gilley, D.; Yoder, M. C., Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood, 2004, 104 (9), 2752-2760.
53. Kawaguchi, T.; Nakamura, K., [Cancer metastasis and blood vessels]. Gan To Kagaku Ryoho, 1983, 10 (7), 1569-1576.
54. Fiedler, W.; Graeven, U.; Ergun, S.; Verago, S.; Kilic, N.; Stockschlader, M.; Hossfeld, D. K., Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 1997, 89 (6), 1870-1875.
55. Ilic, D.; Furuta, Y.; Kanazawa, S.; Takeda, N.; Sobue, K.; Nakatsuji, N.; Nomura, S.; Fujimoto, J.; Okada, M.; Yamamoto, T., Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature, 1995, 377 (6549), 539-544.
56. Furuta, Y.; Ilic, D.; Kanazawa, S.; Takeda, N.; Yamamoto, T.; Aizawa, S., Mesodermal defect in late phase of gastrulation by a targeted mutation of focal adhesion kinase, FAK. Oncogene, 1995, 11 (10), 1989-1995.
57. Ilic, D.; Furuta, Y.; Suda, T.; Atsumi, T.; Fujimoto, J.; Ikawa, Y.; Yamamoto, T.; Aizawa, S., Focal adhesion kinase is not essential for in vitro and in vivo differentiation of ES cells. Biochem. Biophys. Res. Commun., 1995, 209 (1), 300-309.
58. Ilic, D.; Kovacic, B.; McDonagh, S.; Jin, F.; Baumbusch, C.; Gardner, D. G.; Damsky, C. H., Focal adhesion kinase is required for blood vessel morphogenesis. Circ. Res., 2003, 92 (3), 300-307.
59. Shen, T. L.; Park, A. Y.; Alcaraz, A.; Peng, X.; Jang, I.; Koni, P.; Flavell, R. A.; Gu, H.; Guan, J. L., Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J. Cell. Biol., 2005, 169 (6), 941-952.
60. Tang, H.; Hao, Q.; Fitzgerald, T.; Sasaki, T.; Landon, E. J.; Inagami, T., Pyk2/CAKbeta tyrosine kinase activity-mediated angiogenesis of pulmonary vascular endothelial cells. J. Biol. Chem., 2002, 277 (7), 5441-5447.
61. McMullen, M.; Keller, R.; Sussman, M.; Pumiglia, K., Vascular endothelial growth factor-mediated activation of p38 is dependent upon Src and RAFTK/Pyk2. Oncogene, 2004, 23 (6), 1275-1282.
62. Shen, C. J.; Raghavan, S.; Xu, Z.; Baranski, J. D.; Yu, X.; Wozniak, M. A.; Miller, J. S.; Gupta, M.; Buckbinder, L.; Chen, C. S., Decreased cell adhesion promotes angiogenesis in a Pyk2- dependent manner. Exp. Cell Res., 2011.
63. Schultze, A.; Decker, S.; Otten, J.; Horst, A. K.; Vohwinkel, G.; Schuch, G.; Bokemeyer, C.; Loges, S.; Fiedler, W., TAE226- mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis. Invest. New Drugs, 2009.
64. Slack-Davis, J. K.; Martin, K. H.; Tilghman, R. W.; Iwanicki, M.; Ung, E. J.; Autry, C.; Luzzio, M. J.; Cooper, B.; Kath, J. C.; Roberts, W. G.; Parsons, J. T., Cellular characterization of a novel focal adhesion kinase inhibitor. J. Biol. Chem., 2007, 282 (20), 14845-14852.
65. Lim, S. T.; Mikolon, D.; Stupack, D. G.; Schlaepfer, D. D., FERM control of FAK function: implications for cancer therapy. Cell Cycle, 2008, 7 (15), 2306-14.
66. Sieg, D. J.; Ilic, D.; Jones, K. C.; Damsky, C. H.; Hunter, T.; Schlaepfer, D. D., Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK- cell migration. EMBO J., 1998, 17 (20), 5933-5947.
67. Lipinski, C. A.; Loftus, J. C., Targeting Pyk2 for therapeutic intervention. Expert Opin. Ther. Targets, 2010, 14 (1), 95-108.
68. Weis, S. M.; Lim, S. T.; Lutu-Fuga, K. M.; Barnes, L. A.; Chen, X. L.; Gothert, J. R.; Shen, T. L.; Guan, J. L.; Schlaepfer, D. D.; Cheresh, D. A., Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J. Cell. Biol., 2008, 181 (1), 43-50.
69. Shi, Q.; Hjelmeland, A. B.; Keir, S. T.; Song, L.; Wickman, S.; Jackson, D.; Ohmori, O.; Bigner, D. D.; Friedman, H. S.; Rich, J. N., A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol. Carcinog., 2007, 46 (6), 488-496.
70. Liu, T. J.; LaFortune, T.; Honda, T.; Ohmori, O.; Hatakeyama, S.; Meyer, T.; Jackson, D.; de Groot, J.; Yung, W. K., Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol. Cancer Ther., 2007, 6 (4), 1357-67.
71. Beierle, E. A.; Trujillo, A.; Nagaram, A.; Golubovskaya, V. M.; Cance, W. G.; Kurenova, E. V., TAE226 inhibits human neuroblastoma cell survival. Cancer Invest., 2008, 26 (2), 145-151.
72. Golubovskaya, V. M.; Virnig, C.; Cance, W. G., TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol. Carcinog., 2008, 47 (3), 222-234.
73. Kurio, N.; Shimo, T.; Fukazawa, T.; Takaoka, M.; Okui, T.; Hassan, N. M.; Honami, T.; Hatakeyama, S.; Ikeda, M.; Naomoto, Y.; Sasaki, A., Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo. Exp. Cell Res., 2011, 317 (8), 1134-1146.
74. Halder, J.; Lin, Y. G.; Merritt, W. M.; Spannuth, W. A.; Nick, A. M.; Honda, T.; Kamat, A. A.; Han, L. Y.; Kim, T. J.; Lu, C.; Tari, A. M.; Bornmann, W.; Fernandez, A.; Lopez-Berestein, G.; Sood, A. K., Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res., 2007, 67 (22), 10976-10983.
75. Watanabe, N.; Takaoka, M.; Sakurama, K.; Tomono, Y.; Hatakeyama, S.; Ohmori, O.; Motoki, T.; Shirakawa, Y.; Yamatsuji, T.; Haisa, M.; Matsuoka, J.; Beer, D. G.; Nagatsuka, H.; Tanaka, N.; Naomoto, Y., Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Clin. Cancer Res., 2008, 14 (14), 4631-4639.
76. Wang, Z. G.; Fukazawa, T.; Nishikawa, T.; Watanabe, N.; Sakurama, K.; Motoki, T.; Takaoka, M.; Hatakeyama, S.; Omori, O.; Ohara, T.; Tanabe, S.; Fujiwara, Y.; Shirakawa, Y.; Yamatsuji, T.; Tanaka, N.; Naomoto, Y., TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. Oncol. Rep., 2008, 20 (6), 1473-7.
77. Sakurama, K.; Noma, K.; Takaoka, M.; Tomono, Y.; Watanabe, N.; Hatakeyama, S.; Ohmori, O.; Hirota, S.; Motoki, T.; Shirakawa, Y.; Yamatsuji, T.; Haisa, M.; Matsuoka, J.; Tanaka, N.; Naomoto, Y., Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. Mol. Cancer Ther., 2009, 8 (1), 127-134.
78. Hehlgans, S.; Lange, I.; Eke, I.; Cordes, N., 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226. Radiother. Oncol., 2009, 92 (3), 371-378.
79. Din, S., EORTC-NCI-AACR--20th symposium molecular targets and cancer therapeutics. IDrugs, 2008, 11 (12), 855-886.
80. Tanjoni, I.; Walsh, C.; Uryu, S.; Tomar, A.; Nam, J. O.; Mielgo, A.; Lim, S. T.; Liang, C.; Koenig, M.; Sun, C.; Patel, N.; Kwok, C.; McMahon, G.; Stupack, D. G.; Schlaepfer, D. D., PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol. Ther., 2010, 9 (10), 764-777.
81. Walsh, C.; Tanjoni, I.; Uryu, S.; Tomar, A.; Nam, J. O.; Luo, H.; Phillips, A.; Patel, N.; Kwok, C.; McMahon, G.; Stupack, D. G.; Schlaepfer, D. D., Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol. Ther., 2010, 9 (10), 778-790.
82. Golubovskaya, V. M.; Nyberg, C.; Zheng, M.; Kweh, F.; Magis, A.; Ostrov, D.; Cance, W. G., A small molecule inhibitor, 1,2,4,5- benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J. Med. Chem., 2008, 51 (23), 7405-7416.
83. Hochwald, S. N.; Nyberg, C.; Zheng, M.; Zheng, D.; Wood, C.; Massoll, N. A.; Magis, A.; Ostrov, D.; Cance, W. G.; Golubovskaya, V. M., A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle, 2009, 8 (15), 2435-2443.
84. Roberts, W. G.; Ung, E.; Whalen, P.; Cooper, B.; Hulford, C.; Autry, C.; Richter, D.; Emerson, E.; Lin, J.; Kath, J.; Coleman, K.; Yao, L.; Martinez-Alsina, L.; Lorenzen, M.; Berliner, M.; Luzzio, M.; Patel, N.; Schmitt, E.; LaGreca, S.; Jani, J.; Wessel, M.; Marr, E.; Griffor, M.; Vajdos, F., Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res., 2008, 68 (6), 19351944.
85. Dhanie NCBH., Siu LL, Camidge DR, Mileshkin LR, Xu H, Pierce KJ, Fahey NR, FIngert HJ, Shreeve SM In Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors, 2010 ASCO Annual Meeting J. Clin. Oncol., 28: 2010; p abstract 3534.
86. Jones SFSG., Bendell JC, Chen, EX, Bedard P, Cleary JM, Pandya S, Pierce KJ, Houk B, Hosea N, Zandi KS, Roberts WG, Shreeve SM, Siu LL In Phase I study of PF-04554878, a secondgeneration focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors, 2011 ASCO Annual Meeting J. Clin. Oncol., 29: 2011; p abstract 3002.
87. Kurenova, E. V.; Hunt, D. L.; He, D.; Magis, A. T.; Ostrov, D. A.; Cance, W. G., Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J. Med. Chem., 2009, 52 (15), 4716-4724.
88. Strimpakos, A. S.; Syrigos, K. N.; Saif, M. W., Translational research in pancreatic cancer. Highlights from the 2011 ASCO Gastrointestinal Cancers Symposium. San Francisco, CA, USA. January 20-22, 2011. JOP, 2011, 12 (2), 120-122.